CD1a in human cancers: A new role for an old molecule

Trends in Immunology

Volumn 25, Issue 5, 2004, Pages 242-248

  Coventry, Brendon ^a   Heinzel, Susanne ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; GANGLIOSIDE; GANGLIOSIDE GM3; GLYCOLIPID; N GLYCOSYLGANGLIOSIDE GM3; T6 ANTIGEN; TUMOR VACCINE; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ANTIGEN STRUCTURE; BLADDER CANCER; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CELL ACTIVATION; CELL DENSITY; CELL SPECIFICITY; CELL SURVIVAL; CLINICAL TRIAL; CRYSTAL STRUCTURE; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG MECHANISM; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; NONHUMAN; PROTEIN FUNCTION; PROTEIN INDUCTION; REGULATORY MECHANISM; REVIEW; STRUCTURE ANALYSIS; T LYMPHOCYTE; TISSUE DISTRIBUTION; TREATMENT OUTCOME; TUMOR; TUMOR REGRESSION; VACCINATION;

ANTIGEN PRESENTATION; ANTIGENS, CD1; ANTIGENS, NEOPLASM; DENDRITIC CELLS; GANGLIOSIDES; GENE EXPRESSION REGULATION; GLYCOLIPIDS; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MODELS, IMMUNOLOGICAL; NEOPLASMS; SURVIVAL ANALYSIS; T-LYMPHOCYTES;

EID: 3242679690     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2004.03.002     Document Type: Review

References (75)

1. Dascher C.C., Brenner M.B. Evolutionary constraints on CD1 structure: insights from comparative genomic analysis. Trends Immunol. 24:2003;412-418.
2. Fainboim L., Salamone M.C. CD1: a family of glycolypid-presenting molecules or also immunoregulatory proteins? J. Biol. Regul. Homeost. Agents. 16:2002;125-135.
3. Han M., et al. Polymorphism of human CD1 genes. Tissue Antigens. 54:1999;122-127.
4. Oteo M., et al. Single strand conformational polymorphism analysis of human CD1 genes in different ethnic groups. Tissue Antigens. 53:1999;545-550.
5. Roura-Mir C., Moody D.B. Sorting out self and microbial lipid antigens for CD1. Microbes Infect. 5:2003;1137-1148.
6. Smyth M.J., et al. NKT cells - conductors of tumor immunity? Curr. Opin. Immunol. 14:2002;165-171.
7. Wu D.Y., et al. Cross-presentation of disialoganglioside GD3 to natural killer T cells. J. Exp. Med. 198:2003;173-181.
8. Ulanova M., et al. Participation of CD1 molecules in the presentation of bacterial protein antigens in humans. Scand. J. Immunol. 50:1999;387-393.
9. Ulanova M., et al. Antigen-specific regulation of CD1 expression in humans. J. Clin. Immunol. 20:2000;203-211.
10. Sieling P.A. CD1-restricted T cells: T cells with a unique immunological niche. Clin. Immunol. 96:2000;3-10.
11. Kasinrerk W., et al. CD1 molecule expression on human monocytes induced by granulocyte-macrophage-colony-stimulating factor. J. Immunol. 150:1993;579-584.
12. Sallusto F., Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte-macrophage-colony- stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α J. Exp. Med. 179:1994;1109-1118.
13. Cappello F., et al. CD1a: a novel biomarker for Barrett's metaplasia? Lancet Oncol. 4:2003;497.
14. Coventry B.J., Heinzel S. Reply: Is CD1a involved in anti-tumour immune responses during carcinogenesis? Br. J. Cancer. 90:2004;939.
15. + subset of human blood dendritic cells is a direct precursor of Langerhans cells. J. Immunol. 163:1999;1409-1419.
16. Sieling P.A., et al. CD1 expression by dendritic cells in human leprosy lesions: correlation with effective host immunity. J. Immunol. 162:1999;1851-1858.
17. Thomssen H., et al. IL-3 in combination with IL-4, induces the expression of functional CD1 molecules on monocytes. Cytokine. 8:1996;476-481.
18. Ebner S., et al. A novel role for IL-3: human monocytes cultured in the presence of IL-3 and IL-4 differentiate into dendritic cells that produce less IL-12 and shift Th cell responses toward a Th2 cytokine pattern. J. Immunol. 168:2002;6199-6207.
19. Giuliani A., et al. Influence of Mycobacterium bovis bacillus Calmette Guerin on in vitro induction of CD1 molecules in human adherent mononuclear cells. Infect. Immun. 69:2001;7461-7470.
20. Stenger S., et al. Down-regulation of CD1 on antigen-presenting cells by infection with Mycobacterium tuberculosis. J. Immunol. 161:1998;3582-3588.
21. Kawashima T., et al. Cutting edge: major CD8 T cell response to live Bacillus Calmette-Guerin is mediated by CD1 molecules. J. Immunol. 170:2003;5345-5348.
22. Stockwin L.H., et al. Dendritic cells: immunological sentinels with a central role in health and disease. Immunol. Cell Biol. 78:2000;91-102.
23. Schwaab T., et al. In vivo description of dendritic cells in human renal cell carcinoma. J. Urol. 162:1999;567-573.
24. Suzuki A., et al. Mature dendritic cells make clusters with T cells in the invasive margin of colorectal carcinoma. J. Pathol. 196:2002;37-43.
25. Cao X., et al. CD1 molecules efficiently present antigen in immature dendritic cells and traffic independently of MHC class II during dendritic cell maturation. J. Immunol. 169:2002;4770-4777.
26. Coventry B.J., et al. Dendritic cell density and activation status in human breast cancer - CD1a, CMRF-44, CMRF-56 and CD83 expression. Br. J. Cancer. 86:2002;546-551.
27. Reichert T.E., et al. The number of intratumoral dendritic cells and ζ-chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma. Cancer. 91:2001;2136-2147.
28. Hillenbrand E.E., et al. Immunohistochemical localization of CD1a-positive putative dendritic cells in human breast tumours. Br. J. Cancer. 79:1999;940-944.
29. Coventry B.J. CD1a positive putative tumour infiltrating dendritic cells in human breast cancer. Anticancer Res. 19:1999;3183-3187.
30. Barbour A.H., Coventry B.J. Dendritic cell density and activation status of tumour-infiltrating lymphocytes in metastatic human melanoma: possible implications for sentinel node metastases. Melanoma Res. 13:2003;263-269.
31. Troy A., et al. Phenotypic characterisation of the dendritic cell infiltrate in prostate cancer. J. Urol. 160:1998;214-219.
32. Katsenelson N.S., et al. Human small cell lung carcinoma and carcinoid tumor regulate dendritic cell maturation and function. Mod. Pathol. 14:2001;40-45.
33. Troy A.J., et al. CD1a dendritic cells predominate in transitional cell carcinoma of bladder and kidney but are minimally activated. J. Urol. 161:1999;1962-1967.
34. Troy A.J., et al. Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin. Cancer Res. 4:1998;585-593.
35. Bell D., et al. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J. Exp. Med. 190:1999;1417-1426.
36. Tsuge T., et al. Infiltrating dendritic/langerhans cells in primary breast cancer. Breast Cancer Res. Treat. 59:2000;141-152.
37. Kikuchi K., et al. Dendritic cells in human squamous cell carcinoma of the oral cavity. Anticancer Res. 22:2002;545-557.
38. Laguens G., et al. Human regional lymph nodes draining cancer exhibit a profound dendritic cell depletion as comparing to those from patients without malignancies. Immunol. Lett. 84:2002;159-162.
39. Coventry B.J., et al. Identification and isolation of CD1a positive putative tumour infiltrating dendritic cells in human breast cancer. Adv. Exp. Med. Biol. 417:1997;571-577.
40. Sombroek C.C., et al. Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J. Immunol. 168:2002;4333-4343.
41. Gabrilovich D.I., et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2:1996;1096-1103.
42. Vicari A.P., et al. Tumour escape from immune surveillance through dendritic cell inactivation. Semin. Cancer Biol. 12:2002;33-42.
43. Muller L., et al. Escape mechanisms in tumor immunity: an update. J. Environ. Pathol. Toxicol. Oncol. 21:2002;277-330.
44. Iwamoto M., et al. Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas. Int. J. Cancer. 104:2003;92-97.
45. Bitton R.J., et al. Cancer vaccines: an update with special focus on ganglioside antigens. Oncol. Rep. 9:2002;267-276.
46. Takahashi T., et al. IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients. J. Invest. Dermatol. 112:1999;205-209.
47. Saint F., et al. Do prognostic parameters of remission versus relapse after Bacillus Calmette-Guerin (BCG) immunotherapy exist? Analysis of a quarter century of literature. Eur. Urol. 43:2003;351-361.
48. Molife R., Hancock B.W. Adjuvant therapy of malignant melanoma. Crit. Rev. Oncol. Hematol. 44:2002;81-102.
49. McDermott R.S., et al. Tumor antigens and antigen-presenting capacity in breast cancer. Pathobiology. 70:2002;324-332.
50. Coventry B.J., et al. Lack of IL-2 cytokine expression despite IL-2 messenger RNA transcription in tumor-infiltrating lymphocytes in primary human breast carcinoma: selective expression of early activation markers. J. Immunol. 156:1996;3486-3492.
51. McKallip R., et al. Tumor gangliosides inhibit the tumor-specific immune response. J. Immunol. 163:1999;3718-3726.
52. Morton D.L., et al. Polyvalent melanoma vaccine improves survival of patients with metastatic melanoma. Ann. N. Y. Acad. Sci. 690:1993;120-134.
53. Shen W., Ladisch S. Ganglioside GD1a impedes lipopolysaccharide-induced maturation of human dendritic cells. Cell. Immunol. 220:2002;125-133.
54. Caldwell S., et al. Mechanisms of ganglioside inhibition of APC function. J. Immunol. 171:2003;1676-1683.
55. Peguet-Navarro J., et al. Gangliosides from human melanoma tumors impair dendritic cell differentiation from monocytes and induce their apoptosis. J. Immunol. 170:2003;3488-3494.
56. Wolfl M., et al. Gangliosides inhibit the development from monocytes to dendritic cells. Clin. Exp. Immunol. 130:2002;441-448.
57. Kudo D., et al. Gangliosides expressed by the renal cell carcinoma cell line SK-RC-45 are involved in tumor-induced apoptosis of T cells. Cancer Res. 63:2003;1676-1683.
58. Weiss M., et al. Inhibition of melanoma tumor growth by a novel inhibitor of glucosylceramide synthase. Cancer Res. 63:2003;3654-3658.
59. Thomssen H., et al. Differential effects of interleukin-10 on the expression of HLA class II and CD1 molecules induced by granulocyte-macrophage colony-stimulating factor/interleukin-4. Eur. J. Immunol. 25:1995;2465-2470.
60. Fortsch D., et al. IL-10 converts human dendritic cells into macrophage-like cells with increased antibacterial activity against virulent Mycobacterium tuberculosis. J. Immunol. 165:2000;978-987.
61. McBride J.M., et al. IL-10 alters DC function via modulation of cell surface molecules resulting in impaired T-cell responses. Cell. Immunol. 215:2002;162-172.
62. - dendritic cell subsets differ in their cytokine production profiles, susceptibilities to transfection, and capacities to direct Th cell differentiation. J. Immunol. 165:2000;3584-3591.
63. Rongcun Y., et al. Interferon gamma impairs the ability of monocyte-derived dendritic cells to present tumour-specific and allo-specific antigens and reduces their expression of CD1A, CD80 AND CD4. Cytokine. 10:1998;747-755.
64. Bradley W.G., et al. The novel differentiation of human blood mononuclear cells into CD1a-negative dendritic cells is stimulated in the absence of exogenous cytokines by an extract prepared from pinecones. Int. Immunopharmacol. 3:2003;209-223.
65. + dendritic cells from monocytes: phenotypic and functional characterization. J. Immunol. 168:2002;1131-1138.
66. Aalamian M., et al. Human prostate cancer regulates generation and maturation of monocyte-derived dendritic cells. Prostate. 46:2001;68-75.
67. Goldman S.A., et al. Peritumoral CD1a-positive dendritic cells are associated with improved survival in patients with tongue carcinoma. Arch. Otolaryngol. Head Neck Surg. 124:1998;641-646.
68. Eisenthal A., et al. Expression of dendritic cells in ovarian tumors correlates with clinical outcome in patients with ovarian cancer. Hum. Pathol. 32:2001;803-807.
69. Coventry B.J., Morton J. CD1a-positive infiltrating dendritic cell density and five year survival from human breast cancer. Br. J. Cancer. 89:2003;533-538.
70. Lespagnard L., et al. Tumor-infiltrating dendritic cells in adenocarcinomas of the breast: a study of 143 neoplasms with a correlation to usual prognostic factors and to clinical outcome. Int. J. Cancer. 84:1999;309-314.
71. Ambe K., et al. S-100 protein-positive dendritic cells in colorectal adenocarcinomas. Distribution and relation to the clinical prognosis. Cancer. 63:1989;496-503.
72. Gallo O., et al. Correlations between histopathological and biological findings in nasopharyngeal carcinoma and its prognostic significance. Laryngoscope. 101:1991;487-493.
73. Gallo O., et al. Langerhans cells related to prognosis in patients with laryngeal carcinoma. Arch. Otolaryngol. Head Neck Surg. 117:1991;1007-1010.
74. Tsujitani S., et al. Langerhans cells and prognosis in patients with gastric carcinoma. Cancer. 59:1987;501-505.
75. Zeid N.A., Muller H.K. S100 positive dendritic cells in human lung tumors associated with cell differentiation and enhanced survival. Pathology. 25:1993;338-343.